Clinical Trial Update: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating olaparib beyond progression versus platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Ovarian Cancer | Phase 3 | Status: RECRUITING